Inhibition of granulocyte migration by tiotropium bromide
Open Access
- 1 December 2011
- journal article
- Published by Springer Nature in Respiratory Research
- Vol. 12 (1) , 24
Abstract
Study objectives: Neutrophil influx into the airways is an important mechanism in the pathophysiology of the inflammatory process in the airways of patients with chronic obstructive pulmonary disease (COPD). Previously it was shown that anticholinergic drugs reduce the release of non-neuronal paracrine mediators, which modulate inflammation in the airways. On this basis, we investigated the ability of the long-acting anticholinergic tiotropium bromide to inhibit a) alveolar macrophage (AM)-mediated chemotaxis of neutrophils, and b) cellular release of reactive oxygen species (ROS).Method: AM and neutrophils were collected from 71 COPD patients. Nanomolar concentrations of tiotropium bromide were tested in AM cultured up to 20 h with LPS (1 μg/ml). AM supernatant was tested for TNFα, IL8, IL6, LTB4, GM-CSF, MIPα/β and ROS. It was further used in a 96-well chemotaxis chamber to stimulate the migration of fluorescence labelled neutrophils. Control stimulants consisted of acetylcholine (ACh), carbachol, muscarine or oxotremorine and in part PMA (phorbol myristate acetate, 0.1 μg/ml). Potential contribution of M1-3-receptors was ascertained by a) analysis of mRNA transcription by RT-PCR, and b) co-incubation with selective M-receptor inhibitors.Results: Supernatant from AM stimulated with LPS induced neutrophilic migration which could be reduced by tiotropium in a dose dependent manner: 22.1 ± 10.2 (3 nM), 26.5 ± 18,4 (30 nM), and 37.8 ± 24.0 (300 nM, p < 0.001 compared to non-LPS activated AM). Concomitantly TNFα release of stimulated AM dropped by 19.2 ± 7.2% of control (p = 0.001). Tiotropium bromide did not affect cellular IL8, IL6, LTB4, GM-CSF and MIPα/β release in this setting. Tiotropium (30 nM) reduced ROS release of LPS stimulated AM by 36.1 ± 15.2% (p = 0.002) and in carbachol stimulated AM by 46.2 ± 30.2 (p < 0.001). M3R gene expression dominated over M2R and M1R. Chemotaxis inhibitory effect of tiotropium bromide was mainly driven by M3R inhibition.Conclusion: Our data confirm that inhibiting muscarinic cholinergic receptors with tiotropium bromide reduces TNFα mediated chemotactic properties and ROS release of human AM, and thus may contribute to lessen cellular inflammation.Keywords
This publication has 65 references indexed in Scilit:
- Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPDPulmonary Pharmacology & Therapeutics, 2010
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkB/ERK-dependent mechanismEuropean Journal of Pharmacology, 2008
- Long-Term Effects of Budesonide on Inflammatory Status in COPDCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2008
- Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromideLife Sciences, 2007
- The effect of tiotropium on exacerbations and airflow in patients with COPDEuropean Respiratory Journal, 2006
- Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cellsThe AAPS Journal, 2005
- Neurogenic mechanisms in bronchial inflammatory diseasesAllergy, 2004
- Acetylcholine-induced production of reactive oxygen species in adult rabbit ventricular myocytes is dependent on phosphatidylinositol 3- and Src-kinase activation and mitochondrial KATP channel openingJournal of Molecular and Cellular Cardiology, 2003
- Antibodies against the N-terminus of IL-8 Receptor A Inhibit Neutrophil ChemotaxisBiochemical and Biophysical Research Communications, 1996